Scott Isaacs, MD, Endocrinologist and Weight Loss Specialist

03/05/2026

My thoughts on a new study finding a a sweet spot of 7 hours 18 minutes of sleep a night for lowest insulin resistance risk. Too little or too much sleep raises risk, and big weekend “catch-up” sleep may actually worsen glucose metabolism if you already get enough during the week.

New research suggests that just over 7 hours of nightly sleep is ideal for preventing insulin resistance, a precursor to type 2 diabetes.

02/13/2026

Please vote for “Diabetes meds in MASLD” in the poll on X, to support our article on anti-diabetic therapies in and help keep metabolic liver disease in the spotlight for clinicians and patients.

02/04/2026

Obesity and depression often overlap, and primary care clinicians are on the front line of addressing both. Routine screening, normalizing conversations about mental health, and combining counseling with medication when appropriate can improve outcomes.
https://www.medscape.com/viewarticle/discussing-pathways-patients-obesity-and-depression-2026a10003bp

02/03/2026

Proud to have our paper selected as an Editors’ Choice and contender 🏆
We examine how anti-diabetic medications impact liver outcomes in MASLD and why treatment selection is key for disease progression.
https://fg.bmj.com/content/16/3/239

01/17/2026

Obesity is a chronic disease: when the medicine stops, hunger returns, weight often comes back, and so do problems like diabetes, high blood pressure, and dyslipidemia. My comments on what happens when people stop GLP-1 medications.

New research has found that 50% of patients regain the weight they lost if they stop taking Wegovy and Zepbound

01/06/2026

It was an honor to share my thougts about the pill for NPR Morning Edition.

The Wegovy pill approved in December arrived at pharmacies nationwide on Monday. Patients now have a new way to take the weight loss medication.

09/21/2025

Thrilled that our global consensus on MASLD is featured on the cover of Gastroenterology! This is a tremendous step forward for MASLD awareness, and an incredible honor to coauthor with such a remarkable group of liver experts from around the world.
https://www.gastrojournal.org/article/S0016-5085(25)00632-8/fulltext

09/20/2025

Honored to be asked for comment in The Wall Street Journal on the promise of a higher-dose daily semaglutide pill for weight loss. Expanding options is important, and many patients may benefit from an alternative to current treatments.

08/14/2025

The symptoms of thyroid disease and menopause can overlap, making diagnosis a challenge.
https://health.yahoo.com/your-body/womens-health/menopause/article/menopause-or-thyroid-192720088.html

07/18/2025

Tirzepatide improves metabolic hypogonadism better than transdermal testosterone according to this study presented at . Always happy to give my comments for MedCentral.
https://www.medcentral.com/endocrinology/hormones/tirzepatide-shown-to-tackle-hypogonadism

07/14/2025

It was a privilege to help Andrea Petersen as she explored her journey with continuous glucose monitoring for The Wall Street Journal. Fluctuations in glucose levels are a normal part life, and using a can provide meaningful insights into how the foods you eat impact your body. American Association of Clinical Endocrinology
https://www.wsj.com/health/wellness/zoe-gut-health-test-9d950f8f?st=2yYH3c&reflink=desktopwebshare_permalink

06/11/2025

New research links GLP-1 meds to a 2-fold higher risk of wet age-related macular degeneration in people with type 2 diabetes. While the absolute risk remains low, risk increases with longer use and in older adults. Honored to contribute to this important discussion with Health.

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease that can cause blindness. But researchers stress that more research is needed to understand this relationship.